An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists
- 1 November 2003
- Vol. 62 (5) , 877-882
- https://doi.org/10.1016/s0090-4295(03)00656-3
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- A Phase 3, Multicenter, Open Label, Randomized Study Of Abarelix Versus Leuprolide Plus Daily Antiandrogen In Men With Prostate CancerJournal of Urology, 2002
- A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancerUrology, 2001
- THE GONADOTROPIN-RELEASING HORMONE ANTAGONIST ABARELIX DEPOT VERSUS LUTEINIZING HORMONE RELEASING HORMONE AGONISTS LEUPROLIDE OR GOSERELIN: INITIAL RESULTS OF ENDOCRINOLOGICAL AND BIOCHEMICAL EFFICACIES IN PATIENTS WITH PROSTATE CANCERJournal of Urology, 2001
- Responses to the antagonistic analog of LH-RH (SB-75, cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancerThe Prostate, 1994
- LeuprorelinDrugs & Aging, 1991
- Sudden Death due to Disease Flare with Luteinizing Hormone-Releasing Hormone Agonist Therapy for Carcinoma of the ProstateJournal of Urology, 1990
- Influence of Different Types of Antiandrogens on Luteinizing Hormone-Releasing Hormone Analogue-Induced Testosterone Surge in Patients with Metastatic Carcinoma of the ProstateJournal of Urology, 1990